ABN AMRO Investment Solutions’s Alnylam Pharmaceuticals ALNY Stock Holding History

ABN AMRO Investment Solutions’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.27M	Buy	7,557 +1,790	+31%	+$540K	0.02%	387
2026 Q1	$1.91M	Buy	5,767 +8	+0.1%	+$2.72K	0.02%	363
2025 Q4	$2.29M	Buy	5,759 +4,449	+340%	+$1.97M	0.03%	307
2025 Q3	$597K	Hold	1,310	–	–	0.01%	328
2025 Q2	$427K	Hold	1,310	–	–	0.01%	357
2025 Q1	$354K	Buy	1,310 +99	+8%	+$25.4K	0.01%	362
2024 Q4	$285K	Sell	1,211 -183	-13%	-$48.1K	0.01%	417
2024 Q3	$383K	Buy	+1,394	New	+$363K	0.01%	418

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ABN AMRO Investment Solutions's ALNY Position: Q2 2026 in Review

ABN AMRO Investment Solutions increased its Alnylam Pharmaceuticals (ALNY) stake by 31% in Q2 2026, buying an estimated $540K and bringing the position to 7,557 shares worth $2.27M. The position accounts for 0.02% of the portfolio, ranked #387.

ABN AMRO Investment Solutions first reported a position in ALNY in Q3 2024 and has held it in 8 quarters since. The position peaked at $2.29M in Q4 2025. 785 funds tracked by Wall St. Rank hold ALNY as of Q2 2026.

ABN AMRO Investment Solutions held 7,557 shares of Alnylam Pharmaceuticals worth $2.27M as of Q2 2026.
ABN AMRO Investment Solutions bought 1,790 Alnylam Pharmaceuticals shares in Q2 2026, an estimated $540K.
Alnylam Pharmaceuticals made up 0.02% of ABN AMRO Investment Solutions's portfolio in Q2 2026, its #387 holding.
ABN AMRO Investment Solutions first reported a position in Alnylam Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
ABN AMRO Investment Solutions's Alnylam Pharmaceuticals position peaked at $2.29M in Q4 2025.
785 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2026.

Based on ABN AMRO Investment Solutions's 13F filing for Q2 2026, filed 23 Jul 2026.